Official Episode 3 Video Stream
⚠️ Medical Case Study Review & FDA/WADA Status
Medical Case Study Review & Disclaimer: This article is a personal case study for educational and scientific research purposes only. Wayne Stevenson is a construction superintendent and metabolic researcher, not a licensed physician. Nothing here constitutes clinical medical advice. GLP-1 / GIP therapies and therapeutic peptides are highly powerful, prescription substances—always consult your licensed physician before starting or modifying any protocol.
FDA & WADA Status: BPC-157, TB-500, and other research peptides are currently classified by the FDA under Category 2 (under formal review by the Pharmacy Compounding Advisory Committee as of April 2026), restricting standard compounding by 503A pharmacies. Additionally, both BPC-157 and Thymosin Beta-4 (TB-500) are strictly prohibited at all times by the World Anti-Doping Agency (WADA) for all competitive athletes.
On April 15, 2026, the FDA pulled 11 peptides and 12 compounds total off the Category 2 Do-Not-Compound list. This is the biggest regulatory shift in the peptide space since the original ban went into effect in 2023.
But here’s what the headlines aren’t telling you: removed from the ban list does not mean approved. It does not mean your pharmacy can start compounding tomorrow. It means the formal prohibition has been lifted — and these compounds are now in regulatory limbo.
Think of it like a construction permit. The stop-work order has been lifted. But the building permit has not been issued yet.
What Was the Category 2 Ban?
Since 2023, every peptide we cover on this channel — BPC-157, TB-500, MOTS-c — has been sitting on the Category 2 Do-Not-Compound list. This FDA classification effectively banned every licensed 503A compounding pharmacy from manufacturing these compounds for patients.
Before the ban, your doctor could write a prescription. A compounding pharmacy could legally make it. You received a regulated, tested product.
After the ban, your doctor couldn’t prescribe it. The pharmacy couldn’t compound it. The entire regulated supply chain was severed overnight.
The Underground Market Problem
Demand didn’t disappear — it went underground. Research chemical companies started selling peptides labeled “not for human use” with no batch testing requirements, no sterility standards, and no federal oversight.
As RFK Jr. told Joe Rogan, the ban forced patients who were using peptides under medical supervision straight into an unregulated black market. The FDA caught imported peptide batches with dangerously low purity and contaminants that should never enter a human body.
The ban didn’t eliminate peptides. It eliminated quality control.
All 11 Peptides Under Review
Here are the specific peptides and the specific indications the FDA is evaluating:
| Peptide | Indication Under Review |
|---|---|
| BPC-157 | Ulcerative colitis, gut healing |
| TB-500 (Thymosin Beta-4) | Wound healing |
| KPV | Wound healing, inflammatory conditions |
| MOTS-c | Obesity, osteoporosis |
| Semax | Cerebral ischemia, migraines, trigeminal neuralgia |
| Epitalon | Insomnia |
| DSIP | Opioid withdrawal, chronic insomnia, narcolepsy |
February 2027 Review Batch
- Melanotan II
- Dihexa
- LL-37
- GHK-Cu (injectable)
The PCAC Hearing Timeline
A pharmacy that claims they can compound these peptides today is waving a red flag.
The Pharmacy Compounding Advisory Committee (PCAC) must formally evaluate each compound. The PCAC hearing for BPC-157 and TB-500 is scheduled for the end of July 2026. Even after a favorable recommendation, it triggers a rulemaking process and a public comment period before pharmacies get clearance.
We are still talking months after the hearing before your doctor has a clear legal green light to prescribe.
Research Grade vs. Pharmaceutical Grade
If you are currently sourcing peptides from research chemical companies, you need to understand the risk. Research grade does not mean pharmaceutical grade. Without third-party batch testing, you genuinely do not know what you are injecting.
As a builder, I understand structural integrity. You would never pour a foundation with untested concrete. So why would you inject an untested compound?
3 Things You Should Do Right Now
- Demand a Certificate of Analysis (COA) from your vendor. If they cannot provide independent third-party verification of 99%+ purity, find a new source immediately.
- Submit a public comment to the FDA. The docket is open until July 9, 2026. Docket number: FDA-2025-N-6895 at regulations.gov.
- Start building your relationship with a licensed provider now. When these peptides clear the regulatory pathway, you want to be first in line.
What This Means for the Protocol Series
Every single compound I’ve discussed on this channel — BPC-157, TB-500, Mounjaro Muscle Loss, CJC-1295 DAC vs. Tesamorelin — is on this FDA review list. This regulatory shift validates exactly what we’ve been tracking here.
The science is real. The demand is real. The regulatory pathway is finally opening.
But don’t rush into unregulated sources because you saw a headline claiming peptides are “unbanned.” They are not unbanned yet. They are under formal review. There is a massive difference, and understanding that difference protects your health and your money.
⏭️ NEXT EPISODE PREVIEW
Next week, in Episode 4 of our Recomposition Series, we are going deep into the regenerative peptide stack that completely changed my recovery on the job site: BPC-157 and Thymosin Beta-4 (The Wolverine Stack). We will analyze the molecular pathways, the clinical evidence, the legal regulatory landscape, and my personal research protocols.
⚠️ AI Digital Twin Disclosure
The video content accompanying the Keystone Recomposition brand is hosted by a photorealistic, synthetic visual network representation (AI Digital Twin) of Wayne Stevenson. All real-world job site footage, personal clinical lab work, physical training logs, and research data are authentic and fully documented by the human creator.